Zobrazeno 1 - 10
of 77
pro vyhledávání: '"William Dall'acqua"'
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Complement-dependent cytotoxicity (CDC) is a potent effector mechanism, engaging both innate and adaptive immunity. Although strategies to improve the CDC activity of antibody therapeutics have primarily focused on enhancing the interaction between t
Externí odkaz:
https://doaj.org/article/5ce3a9d83ee34780b0707e2364352601
Autor:
Michael W. Handlogten, Li Peng, Elizabeth A. Christian, Weichen Xu, Shihua Lin, Raghavan Venkat, William Dall’Acqua, Sanjeev Ahuja
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
IgG4s are dynamic molecules that undergo a process called Fab-arm exchange. Disulfide bonds between heavy chains are transiently reduced, resulting in half antibodies that reform intact antibodies with other IgG4 half antibodies. In vivo, therapeutic
Externí odkaz:
https://doaj.org/article/8d31a924751447b982a0b36561feb01c
Autor:
Gargi Roy, Jason Reier, Andrew Garcia, Tom Martin, Megan Rice, Jihong Wang, Meagan Prophet, Ronald Christie, William Dall’Acqua, Sanjeev Ahuja, Michael A Bowen, Marcello Marelli
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
The ability to genetically encode non-natural amino acids (nnAAs) into proteins offers an expanded tool set for protein engineering. nnAAs containing unique functional moieties have enabled the study of post-translational modifications, protein inter
Externí odkaz:
https://doaj.org/article/620783070d4e40d9956638da05776be1
Autor:
Elizabeth M. Bruckheimer, Christine A. Fazenbaker, Sandra Gallagher, Kathy Mulgrew, Stacy Fuhrmann, Karen T. Coffman, William Walsh, Shannon Ready, Kim Cook, Melissa Damschroder, Michael Kinch, Peter A. Kiener, Rob Woods, Changshou Gao, William Dall'Acqua, Herren Wu, Steven Coats
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 11, Iss 6, Pp 509-517 (2009)
EphA2 is a receptor tyrosine kinase that has been shown to be overexpressed in a variety of human tumor types. Previous studies demonstrated that agonist monoclonal antibodies targeting EphA2 induced the internalization and degradation of the recepto
Externí odkaz:
https://doaj.org/article/acc76d8483d74cb9bab7bf45680fe3a8
Autor:
Xiaodong Xiao, Yan Chen, Sheila Mugabe, Changshou Gao, Christine Tkaczyk, Yariv Mazor, Peter Pavlik, Herren Wu, William Dall'Acqua, Partha Sarathi Chowdhury
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140691 (2015)
High throughput screenings of single chain Fv (scFv) antibody phage display libraries are currently done as soluble scFvs produced in E.coli. Due to endotoxin contaminations from bacterial cells these preparations cannot be reliably used in mammalian
Externí odkaz:
https://doaj.org/article/e29aa299e6034259ac0c9190cd45e5de
Autor:
Li Peng, Michael D Oberst, Jiaqi Huang, Philip Brohawn, Chris Morehouse, Kristen Lekstrom, Patrick A Baeuerle, Herren Wu, Yihong Yao, Steven R Coats, William Dall'Acqua, Melissa Damschroder, Scott A Hammond
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e36412 (2012)
MEDI-565 (also known as MT111) is a bispecific T-cell engager (BiTE®) antibody in development for the treatment of patients with cancers expressing carcinoembryonic antigen (CEA). MEDI-565 binds CEA on cancer cells and CD3 on T cells to induce T-cel
Externí odkaz:
https://doaj.org/article/da294e9bbf4741419797c4c6311d44f6
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
Supplementary Materials and Methods, and Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238b4ab5c831dd6063dffdf564c8ad3c
https://doi.org/10.1158/2159-8290.22540037
https://doi.org/10.1158/2159-8290.22540037
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca7eaed273b219faf1bb63ec9cf8694
https://doi.org/10.1158/2159-8290.c.6549263
https://doi.org/10.1158/2159-8290.c.6549263
Autor:
Gabriela M. Marchetti, Jennifer Cann, Keith W Rickert, Ruchi Gupta, Weiguang Zhao, Qing Li, Jonathan T. Boyd, Richard N. Hanna, Timothy Burwell, Herren Wu, M. Jack Borrok, William Dall'acqua, Joseph Grimsby, Emily L. Ongstad, Norman C. Peterson, Ping Tsui, Maureen Kennedy
Publikováno v:
Communications Biology, Vol 2, Iss 1, Pp 1-10 (2019)
Communications Biology
Communications Biology
Systemic administration of bio-therapeutics can result in only a fraction of drug reaching targeted tissues, with the majority of drug being distributed to tissues irrelevant to the drug’s site of action. Targeted delivery to specific organs may al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32077e33fd53ad432f6d3fc3ce090745
http://link.springer.com/article/10.1038/s42003-019-0337-2
http://link.springer.com/article/10.1038/s42003-019-0337-2
Autor:
Simon J, Dovedi, Matthew J, Elder, Chunning, Yang, Suzanne I, Sitnikova, Lorraine, Irving, Anna, Hansen, James, Hair, Des C, Jones, Sumati, Hasani, Bo, Wang, Seock-Ah, Im, Ben, Tran, Deepa S, Subramaniam, Shelby D, Gainer, Kapil, Vashisht, Arthur, Lewis, Xiaofang, Jin, Stacy, Kentner, Kathy, Mulgrew, Yaya, Wang, Michael G, Overstreet, James, Dodgson, Yanli, Wu, Asis, Palazon, Michelle, Morrow, Godfrey J, Rainey, Gareth J, Browne, Frances, Neal, Thomas V, Murray, Aleksandra D, Toloczko, William, Dall'Acqua, Ikbel, Achour, Daniel J, Freeman, Robert W, Wilkinson, Yariv, Mazor
Publikováno v:
Cancer discovery. 11(5)
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9cee0afaa71445587217670a975d51b1
https://pubmed.ncbi.nlm.nih.gov/33947716
https://pubmed.ncbi.nlm.nih.gov/33947716